Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today ...

Privately-held US biotech Skyhawk Therapeutics has announced a strategic research collaboration with Germany’s Merck KGaA ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The US Food and Drug Administration (FDA) granted approval for a second treatment for metabolic dysfunction-associated ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a ...